M.E. Elez Fernandez

LBA28 The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients

Sara Lonardi, Filippo Pietrantonio, N. Tarazona Llavero et al. · Annals of Oncology · 2023 · 58 citations · Full text

Medicine, Oncology, Surgery +16

LBA25 FRESCO-2: A global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer

N.A. Dasari, Sara Lonardi, Rocio García‐Carbonero et al. · Annals of Oncology · 2022 · 27 citations · Full text

Medicine, Oncology, Pharmacology +9

LBA32 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study

K-K. Shiu, Thierry André, Tae Won Kim et al. · Annals of Oncology · 2023 · 21 citations · Full text

Medicine, Oncology, Chemotherapy +13

LBA26 BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC)

Josep Tabernero, T. Yoshino, T.W. Kim et al. · Annals of Oncology · 2022 · 13 citations

Medicine, Oncology, Pharmacology +11

613P Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial

Gerald W. Prager, Marwan Fakih, Fortunato Ciardiello et al. · Annals of Oncology · 2023 · 10 citations · Full text

Medicine, Oncology, Pharmacotherapy +17